MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer
Valentine, Helen R
Brown, Michael D
Ramani, Vijay A C
Clarke, Noel W
Hoskin, Peter J
West, Catharine ML
AffiliationCRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK
MetadataShow full item record
AbstractPURPOSE: Organ-confined muscle-invasive bladder cancer (MIBC) is treated with cystectomy or bladder preservation techniques, including radiotherapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed high levels of MRE11 protein, assessed by immunohistochemistry (IHC), predicted outcome following radiotherapy but not cystectomy. Therefore, we sought to develop the MRE11 IHC assay for clinical use and define its relationship to clinical outcome in samples from two major clinical trials. METHODS AND MATERIALS: Samples from the BCON and BC2001 randomised controlled trials and a cystectomy cohort were stained using automated IHC methods and scored for MRE11 in three UK centres. RESULTS: Despite step-wise creation of scoring cards and standard operating procedures for staining and interpretation, there was poor inter-centre scoring agreement (Kappa 0.32, 95% CI 0.17-0.47). There were no significant associations between MRE11 scores and cause-specific survival (CSS) identified in BCON (n=132) and BC2001 (n=221) samples. Re-optimised staining improved agreement between scores from BCON tissue microarrays (n=116), but MRE11 expression was not prognostic for CSS. CONCLUSIONS: Manual IHC scoring of MRE11 was not validated as a reproducible biomarker of radiation-based bladder preservation success. There is a need for automated quantitative methods and/or a reassessment of how DNA-damage response relates to clinical outcomes.
CitationWalker AK, Karaszi K, Valentine H, Strauss VY, Choudhury A, McGill S, et al. MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer. Int J Radiat Oncol Biol Phys. 2019.
JournalInternational Journal of Radiation Oncology, Biology, Physics
- MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
- Authors: Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, Kiltie AE
- Issue date: 2010 Sep 15
- Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.
- Authors: Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhøi BP, Agerbaek M, Hartmann A, Bertz S, Wittlinger M, Fietkau R, Rödel C, Borre M, Jensen JB, Orntoft T, Dyrskjøt L
- Issue date: 2012 Dec
- Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.
- Authors: Teo MTW, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Ørntoft TF, Bishop DT, Kiltie AE
- Issue date: 2014 Apr
- Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours.
- Authors: Martin RM, Kerr M, Teo MT, Jevons SJ, Koritzinsky M, Wouters BG, Bhattarai S, Kiltie AE
- Issue date: 2014 Feb 28
- Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
- Authors: Turker P, Segersten U, Malmström PU, Hemdan T
- Issue date: 2019 Feb